The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 7.80 — safe zoneOK
Leadership changes
From ORAMED PHARMACEUTICALS INC.'s own filings, the day they're filed.
- Leonard Sank · directors · departureeff. 2026-01-01
- David Silberman · Chief Financial Officer · departureeff. 2024-07-12
- Avraham Gabay · Chief Financial Officer · appointmenteff. 2024-06-18
Latest filings
- 10-Q · Quarterly report2026-08-10
- DEF 14A · Annual proxy (pay & governance)2026-08-03
- 8-K · Company announcement2026-06-30
- 10-Q · Quarterly report2026-05-19
- 8-K · Company announcement2026-03-31
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about ORAMED PHARMACEUTICALS INC., every answer cited to the official filings🔒
- The Intelligence Brief — added when ORAMED PHARMACEUTICALS INC.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.